These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 29803351)

  • 1. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies.
    Corona G; Rastrelli G; Di Pasquale G; Sforza A; Mannucci E; Maggi M
    J Sex Med; 2018 Jun; 15(6):820-838. PubMed ID: 29803351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk.
    Khera M; Miner M; Jaffe J; Pastuszak AW
    J Sex Med; 2021 Jan; 18(1):83-98. PubMed ID: 33317996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous Testosterone Levels and Cardiovascular Risk: Meta-Analysis of Observational Studies.
    Corona G; Rastrelli G; Di Pasquale G; Sforza A; Mannucci E; Maggi M
    J Sex Med; 2018 Sep; 15(9):1260-1271. PubMed ID: 30145097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Testosterone replacement therapy and cardiovascular risk].
    Corona G; Dicuio M; Rastrelli G; Sforza A; Maggi M
    G Ital Cardiol (Rome); 2017 Nov; 18(11):745-753. PubMed ID: 29105668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular impact of testosterone therapy for hypogonadism.
    Rastrelli G; Dicuio M; Reismann Y; Sforza A; Maggi M; Corona G
    Expert Rev Cardiovasc Ther; 2018 Sep; 16(9):617-625. PubMed ID: 30099911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone.
    Fallara G; Pozzi E; Belladelli F; Corsini C; Boeri L; Capogrosso P; Montorsi F; Salonia A
    J Sex Med; 2022 Aug; 19(8):1243-1254. PubMed ID: 35753891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome.
    Hackett G
    Sex Med Rev; 2019 Jul; 7(3):476-490. PubMed ID: 30803918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone Therapy: What We Have Learned From Trials.
    Corona G; Torres LO; Maggi M
    J Sex Med; 2020 Mar; 17(3):447-460. PubMed ID: 31928918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternatives to Testosterone Therapy: A Review.
    Lo EM; Rodriguez KM; Pastuszak AW; Khera M
    Sex Med Rev; 2018 Jan; 6(1):106-113. PubMed ID: 29174957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety of testosterone replacement therapy in men: an updated systematic review and meta-analysis.
    Corona G; Rastrelli G; Sparano C; Carinci V; Casella G; Vignozzi L; Sforza A; Maggi M
    Expert Opin Drug Saf; 2024 May; 23(5):565-579. PubMed ID: 38553429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone treatment and cardiovascular and venous thromboembolism risk: what is 'new'?
    Corona G; Dicuio M; Rastrelli G; Maseroli E; Lotti F; Sforza A; Maggi M
    J Investig Med; 2017 Aug; 65(6):964-973. PubMed ID: 28495861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis.
    Corona G; Maseroli E; Rastrelli G; Isidori AM; Sforza A; Mannucci E; Maggi M
    Expert Opin Drug Saf; 2014 Oct; 13(10):1327-51. PubMed ID: 25139126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials.
    Haddad RM; Kennedy CC; Caples SM; Tracz MJ; Boloña ER; Sideras K; Uraga MV; Erwin PJ; Montori VM
    Mayo Clin Proc; 2007 Jan; 82(1):29-39. PubMed ID: 17285783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on heart disease risk associated with testosterone boosting medications.
    Corona G; Rastrelli G; Guaraldi F; Tortorici G; Reismann Y; Sforza A; Maggi M
    Expert Opin Drug Saf; 2019 Apr; 18(4):321-332. PubMed ID: 30998433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythrocytosis Following Testosterone Therapy.
    Ohlander SJ; Varghese B; Pastuszak AW
    Sex Med Rev; 2018 Jan; 6(1):77-85. PubMed ID: 28526632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups.
    Traish AM; Haider A; Haider KS; Doros G; Saad F
    J Cardiovasc Pharmacol Ther; 2017 Sep; 22(5):414-433. PubMed ID: 28421834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone deficiency and cardiovascular mortality.
    Morgentaler A
    Asian J Androl; 2015; 17(1):26-31. PubMed ID: 25432501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trials - mechanistic studies of testosterone and the cardiovascular system.
    Jones TH; Kelly DM
    Asian J Androl; 2018; 20(2):120-130. PubMed ID: 29442075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.
    Haider A; Yassin A; Haider KS; Doros G; Saad F; Rosano GM
    Vasc Health Risk Manag; 2016; 12():251-61. PubMed ID: 27366080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk.
    Miner M; Morgentaler A; Khera M; Traish AM
    Clin Endocrinol (Oxf); 2018 Jul; 89(1):3-10. PubMed ID: 29486065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.